Tubulis GmbH’s Post

Today, we announced preclinical data for potential first-in-class medicines, including FHD-909, a BRM (SMARCA2) selective inhibitor, and our selective CBP degrader and selective EP300 degrader programs at the 2024 American Association for Cancer Research Annual Meeting. Learn about the data, and don't forget to register for the webcast at 5 pm ET: https://bit.ly/4aOkbZz #biotechnology #innovation #oncology #drugdevelopment #AACR24

There’s no better time to start your data capture of in vivo oncology, in vitro, and biomarker studies with CrownLink™. Our customer portal is designed to fit your needs with benefits of capturing and monitoring study data without the hassle of a manual process. Experience the benefits of a streamlined workflow today. Register for free https://bit.ly/3tOGXRo #InVitro #InVivo #Oncology #Biomarkers #Biotech #Bioscience

The Sapience Therapeutics, Inc. team is excited to share that we will present new clinical efficacy and biomarker data from our Phase 2 clinical study of ST101 in glioblastoma during an oral presentation at #ASCO24.    Learn more here: https://bit.ly/4b42J41   #Biotechnology #Oncology #glioblastoma #gbm

Multi-Omics/Multi-Dimensional data sets are needed to accelerate getting therapies to the clinic. Champions Oncology, Inc. have proven the value of advancing R&D with multi-omics/multi-dimensional data sets and are here to help the Pharmaceutical and Biotech industry do the same!

🚀 New Blog Series: Complexity Spectrum in Clinical Trials. We’re excited to kick off a three-part series with our latest blog post, exploring the 'Complexity Spectrum' in clinical trials. Part One dives into a low-complexity prostate cancer trial, highlighting how configurable and flexible approaches are tailored to optimize trial execution. Stay tuned as we continue this series, showcasing strategies for tackling medium and high-complexity trials, ultimately driving the development of more effective therapies 𝗥𝗲𝗮𝗱 𝗣𝗮𝗿𝘁 𝗢𝗻𝗲 𝗵𝗲𝗿𝗲: https://bit.ly/4csHYP1 #ClinicalTrials #HealthcareInnovation #PrecisionMedicine #ProstateCancer #Pharma #Biotech #Oncology #4GClinical

🎤 Our CEO, Dr. Murali Ramachandra, will be presenting Aurigene Oncology Limited’s innovative approach to developing Pan-KRAS degraders at the 22nd Annual Discovery on Target conference, to be held from 🗓 Sept 30th – Oct 3rd in 📍 Boston, MA.   🔎 Leveraging our proprietary Directed Neo-substrate Degrader (DNsD) platform, the lead molecule has been optimized to effectively degrade all tested mutant KRAS proteins while maintaining exquisite selectivity over HRAS and NRAS. The nomination of the development candidate is anticipated in 🗓 Q4 2024. The conference is organized by Cambridge Healthtech Institute #BostonDOT24 #Cancer #Oncology #KRAS #PlatformTechnologies #Degraders #mutations #CancerTargets #CancerResearch #precisiononcology #OncologyTargets #OncologyPipeline #SmallMolecules #Immunooncology #DrugDiscovery #CancerTreatment #OncologyConferences #Networking #BusinessDevelopment #Partnerships #BusinessDevelopmentProfessionals #Boston #USA #Healthcare #Pharma #Pharmaceuticals

Heidelberg Pharma AG, first in the world to develop amanitin for cancer therapy, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. Heidelberg Pharma AG uses its proprietary ADC payload (ATAC® technology) to develop ADCs called ATACs that have amanitin-based compounds as the payload.     Why is Heidelberg Pharma AG a company to watch?  Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/eCSaAWtu #oncology #cancertreatement #biotech #pharma #companiestowatch 

🚀 Presenting ADC Digest for April 2024! 🔬 💊Adcentrx Therapeutics to showcase Preclinical findings of Nectin-4 ADC Program at AACR Annual Meeting 2024 💊Datopotamab deruxtecan BLA accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer 💊Ipsen licenses Sutro ADC in $900m deal 💊Caris Life Sciences partners with Merck KGaA to discover cancer targets and fast-track ADC development Stay tuned for more updates and breakthroughs in the world of Antibody-Drug Conjugates! 💪🔬 #ADC #CancerResearch #Innovation #ADCnews #CIScientists #Antibodydrugconjugate

🔄 Merck & Co. Makes Strategic Moves in ADC Pipeline with Kelun-Biotech 💊💥 In a significant pipeline update, Merck & Co. is making waves in the antibody-drug conjugate (ADC) space! Merck has exercised its option on SKB571, a promising bispecific ADC targeting solid tumors like lung and gastrointestinal cancers, with a $37.5M payment to Kelun-Biotech. 💰🔬 While advancing SKB571, Merck has also opted to return the global rights to another ADC, SKB315, which targets CLDN18.2—a crowded field with multiple contenders. Kelun will continue to develop SKB315, focusing on the Chinese market, where early data shows positive results in gastric cancer. 📈🌍 This move sharpens Merck's focus on high-potential assets while streamlining its ADC portfolio. With the ADC space heating up, it's clear Merck is positioning itself for targeted growth! 🚀 #Merck #KelunBiotech #ADC #PharmaNews #Biotech #CancerResearch #Oncology #DrugDevelopment #HealthcareInnovation #PipelineUpdate #LinkedInNews

After spending some time reflecting on our time at ASCO 2024, Magnolia is thrilled to share our recent whitepaper on the evolving landscape of precision medicine in oncology, a key topic of discussion at the conference. This paper summarizes key trends from ASCO including biomarker reevaluation, targeted therapy augmentation, dosing optimization, and pan-tumor applications. We dive into implications for market research and pharma strategy to account for these shifting mindsets in patient management. Check it out here https://lnkd.in/gyAX_YBW or reach out to us if you would like to learn more about our ongoing work to stay on the cutting edge of the oncology space.   #PrecisionMedicine #Oncology #ASCO2024 #Marketresearch #healthsciences #MagnoliaInnovation